NASDAQ · Health care

Corvus Pharmaceuticals, Inc. (CRVS)

It posted a net loss of $54.1M. In fiscal 2025 capital spending exceeded operating cash flow by $33M. At June 30, 2026 it held $18.9M in cash. Its latest periodic report to the SEC is the quarterly report (10-Q) filed on August 6, 2026.

Price

$11.62

-1.53% on the day · September 25, 2026

52-week range $6.39 to $26.95

Market cap

$977.5M

What Corvus Pharmaceuticals, Inc. does

Corvus Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CRVS.

Revenue and profit by year

Net income

Fiscal years as reported in annual reports. Amounts in USD.

Key figures

Fiscal year	Revenue	Operating income	Net income	Diluted EPS	Free cash flow
2025	n/a	-$43M	-$15.3M	-$0.53	-$33M
2024	n/a	-$27.5M	-$62.3M	-$1.02	n/a
2023	n/a	-$23.4M	-$27M	-$0.56	-$24M
2021	n/a	-$32.6M	-$41.3M	-$0.89	-$27.3M
2021	n/a	-$38.6M	-$43.2M	-$1.03	-$36.7M
2020	n/a	-$43.8M	-$6M	-$0.20	-$34.9M

Next report expected around November 3, 2026.

Estimated from its filing rhythm: 52 weeks after its report of November 4, 2025. Not a date the company has announced. See the report calendar

Latest SEC filings

What Corvus Pharmaceuticals, Inc. has filed recently, newest first. Each links to the original document on SEC EDGAR.

August 7, 2026
Passive stake (5% or more) SCHEDULE 13G
August 6, 2026
Quarterly report 10-Q · period to June 30, 2026
August 6, 2026
Quarterly results 8-K
July 27, 2026
Passive stake changed SCHEDULE 13G/A
July 22, 2026
Executive or director change 8-K
June 12, 2026
Shareholder vote results 8-K
May 15, 2026
Passive stake changed SCHEDULE 13G/A
May 15, 2026
Passive stake (5% or more) SCHEDULE 13G
May 14, 2026
Investor disclosure 8-K
May 7, 2026
Employee stock plan registration S-8

Recent insider filings (Forms 3, 4 and 144): 10, the latest on June 15, 2026. Insider transactions on SEC

Insider trades

What the people running Corvus Pharmaceuticals, Inc. did with its shares, from the Form 4 filings they must send the SEC within two business days.

No insider trades were reported in the last 90 days.

Bought (open market)

last 90 days

Sold

last 90 days

All insider filings on SEC.gov · Where insiders are buying across the market

All filings on SEC EDGAR

Questions about CRVS

What does Corvus Pharmaceuticals, Inc. do?

Corvus Pharmaceuticals, Inc. is registered with the SEC under industry code SIC 2834 (Pharmaceutical Preparations). Its shares trade on NASDAQ under the ticker CRVS.

Is Corvus Pharmaceuticals, Inc. profitable?

No. Over the twelve months to June 30, 2026 it reported a net loss of $54.1M.

When did Corvus Pharmaceuticals, Inc. last report?

Its most recent periodic report is the quarterly report (10-Q) filed on August 6, 2026. It covers the period to June 30, 2026. Its newest filing of any kind is the passive stake (5% or more) from August 7, 2026.

Similar companies

Compare CRVS with

Compare CRVS with any company

Follow CRVS

Get an email when Corvus Pharmaceuticals, Inc. files with the SEC: results, executive changes, material agreements and annual reports.

Follow CRVS: get an email when it files

Where the numbers come from

Financial figures are the values Corvus Pharmaceuticals, Inc. tagged in its own SEC filings (XBRL), taken from the latest filing for each period, so restatements replace older figures. Revenue, profit and cash flow are for full fiscal years unless marked as the last twelve months, which is the sum of the four most recent quarters. Where a company reports only the full year, the fourth quarter is the year minus the first three.

Prices are delayed end-of-day market data in the listing currency, and market cap moves with the price. P/E is shown only when earnings per share are positive. Nothing here is investment advice.